Core Viewpoint - Junshi Biosciences (01877) experienced a significant stock increase of over 10%, attributed to the approval of clinical trial application for JT118, a dual-target recombinant protein vaccine aimed at preventing monkeypox virus infection [1] Group 1: Clinical Trial Approval - Junshi Biosciences' subsidiary, Shanghai Juntuo Biopharmaceutical Technology Co., Ltd., received the Drug Clinical Trial Approval Notification from the National Medical Products Administration for JT118 [1] - JT118 is a recombinant protein vaccine composed of monkeypox virus antigens A35 and M1, demonstrating significant protective effects in preclinical studies against both vaccinia virus and monkeypox virus in large animal models, with good safety profiles [1] Group 2: Research Recognition - Multiple research outcomes from Junshi Biosciences, including the anti-BTLA monoclonal antibody tifcemalimab and the anti-PD-1 monoclonal antibody treprilumab, have been selected for oral presentations and posters at the 2025 World Lung Cancer Conference (WCLC) scheduled for September 6-9, 2025, in Barcelona, Spain [1]

消息面上，君实生物发布公告，近日，公司控股子公司上海君拓生物医药科技有限公司收到国家药品监 督管理局核准签发的《药物临床试验批准通知书》，JT118注射液(项目代号"JT118")的临床试验申请获 得批准。JT118是由猴痘病毒抗原A35(胞外囊膜病毒抗原)和M1(胞内成熟病毒抗原)串联融合组成的"二 合一"重组蛋白疫苗，拟主要用于预防猴痘病毒感染。临床前研究结果表明，JT118对痘苗病毒/猴痘病 毒感染的大小动物模型均具有显著的保护作用，且安全性良好。 另外，2025年世界肺癌大会(WCLC)将于2025年9月6日至9日在西班牙巴塞罗那举行。君实生物创新产 品抗BTLA单抗tifcemalimab、抗PD-1单抗特瑞普利单抗多项研究成果入选大会口头报告和壁报，详细展 示肺癌领域最新研究进展。 君实生物(01877)涨超10%，截至发稿，涨11.03%，报34.22港元，成交额5.16亿港元。 ...